Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06233942 · ClinicalTrials.gov registry record · Phase 1
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumor, sponsored by BeOne Medicines.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 308
- Enrollment target
- 20
- Study locations
NCT06233942: Recruiting Phase 1 study of Advanced Solid Tumor, sponsored by BeOne Medicines.
NCT06233942 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by BeOne Medicines. The registered enrollment target is 308 participants, above the 191-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (61% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06233942, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by BeOne Medicines.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 308 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a first-in-human, dose finding and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C9074 alone and in combination with other anticancer therapies in patients with advanced solid tumors.
Primary Outcome
Number of participants with AEs and SAEs (as graded by the National Cancer Institute-Common Terminology Criteria for Adverse Events \[NCI-CTCAE\] Version \[v\] 5.0),, including findings from physical examinations, electrocardiograms (ECGs), laboratory assessments, and that meet protocol-defined dose-limiting toxicity criteria.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Tislelizumab
- DRUG BG-C9074
Study Locations (20)
Other
- Hospital Sirio Libanes Brasilia - Brasília
- Liga Norte Riograndene Contra O Cancer - Natal
- Hospital Sao Lucas Da Pucrs - Porto Alegre
- Instituto Nacional de Cancer Hospital Do Cancer Ii - Rio de Janerio
- Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto - São José do Rio Preto
- Icesp Instituto Do Cancer Do Estado de Sao Paulo Octavio Frias de Oliveira - São Paulo
- Clinica de Pesquisa E Centro de Estudos Em Oncologia Ginecologica E Mamaria - São Paulo
New South Wales
- Blacktown Cancer and Haematology Centre - Blacktown
- Macquarie University - North Ryde
- Cancer Care Wollongong - Wollongong
Victoria
- Monash Health - Clayton
- Cabrini Hospital Malvern - Malvern East
- Peter Maccallum Cancer Centre - Melbourne
California
- Usc Norris Comprehensive Cancer Center (Nccc) - Los Angeles
Colorado
- University of Colorado Cancer Center - Aurora
Florida
- Florida Cancer Specialist Research Institute Lake Nona - Orlando
Maryland
- Sidney Kimmel Comprehensive Cancer At Johns Hopkins - Baltimore
Ohio
- James Cancer Hospital and Solove Research Institute - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 308 participants |
| Start Date | 2024-04-12 |
| Est. Completion | 2028-05-15 |
| Phase | Phase 1 |
What NCT06233942 shows while recruiting
NCT06233942 is an interventional study that assigns participants to a tested intervention. The registered 308 participants enrollment target is mid-sized for trials with a published cap, above the 191-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (61% higher).
The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.
NCT06233942 names 20 study sites across 10 states, led by Other, New South Wales, Victoria.
Frequently Asked Questions
What is clinical trial NCT06233942 about?
NCT06233942 is a clinical study titled "Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors". This is a first-in-human, dose finding and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C9074 alone and in combination with other anticancer therapies in patients with advanced solid tumors.
What is the current status of trial NCT06233942?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 308 participants. The study started on 2024-04-12. Estimated completion is 2028-05-15.
What conditions does trial NCT06233942 study?
This clinical trial studies the following conditions: Advanced Solid Tumor.
What interventions are being tested in trial NCT06233942?
The interventions under investigation include: Bevacizumab (DRUG), Tislelizumab (DRUG), BG-C9074 (DRUG).
Who is sponsoring clinical trial NCT06233942?
This trial is sponsored by BeOne Medicines, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06233942 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Maryland, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06233942's enrollment target sits among peer trials
308 36th of 189 higher than 154 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04162938 · 308 participants · NA
Use of a Patient-Centered Electronic App to Increase ED Patient's Knowledge on HCV to Improve the HCV Care Continuum
- NCT04955795 · 308 participants · NA
Telemedicine for Unhealthy Alcohol Use in Persons Living With HIV Using CETA
- NCT06090539 · 308 participants · Phase 1
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
- NCT06319248 · 308 participants · Phase 2
MID-STEP (MIDodrine for Sepsis Treatment and Early vasoPressor Weaning) Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI